Notably, prior to the appointments of Kelly and Aromando, Oncolytics presented new GOBLET data at the 2025 ASCO Annual ...

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces the development of novel ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS- ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

Researchers have identified a mutation in a common oncogene that may play an important role in colon cancer. Their findings ...

A new study [1] from the Medical University of Vienna has uncovered a surprising vulnerability in colorectal cancers driven ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the ...

Despite a robust cash position, Revolution Medicines' high burn rate and lofty valuation increase risk and sensitivity to ...